You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR CEFZIL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CEFZIL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00778245 ↗ Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions Completed Ranbaxy Laboratories Limited N/A 2005-05-01 The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.
NCT00778557 ↗ Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions Completed Ranbaxy Laboratories Limited N/A 2005-06-01 The study was conducted as a blinded, randomized, 3-way crossover study to compare the single-dose relative bioavailability of Cefprozil 250 mg/5 mL Oral suspension versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) following one 5 mL dose under fasting conditions
NCT00778739 ↗ Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fed Conditions Completed Ranbaxy Laboratories Limited N/A 2005-06-01 The study was conducted as an open-label, randomized, 2-way crossover study to compare the single-dose relative bioavailability of Cefprozil 250 mg/5 mL Oral suspension versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) following one 5 mL dose under fed conditions
NCT00778778 ↗ Bioequivalence Study of Cefprozil Tablets, USP 500 mg Under Fasting Conditions Completed Ranbaxy Laboratories Limited N/A 2005-05-01 The objective of this study was to assess the single-dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fasting conditions.
NCT00835354 ↗ Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting Completed Teva Pharmaceuticals USA Phase 1 2004-05-01 The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under non-fasting conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CEFZIL

Condition Name

Condition Name for CEFZIL
Intervention Trials
Healthy 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CEFZIL
Intervention Trials
Disease 2
Malnutrition 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CEFZIL

Trials by Country

Trials by Country for CEFZIL
Location Trials
United States 6
Canada 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CEFZIL
Location Trials
Missouri 4
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CEFZIL

Clinical Trial Phase

Clinical Trial Phase for CEFZIL
Clinical Trial Phase Trials
Phase 1 8
N/A 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CEFZIL
Clinical Trial Phase Trials
Completed 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CEFZIL

Sponsor Name

Sponsor Name for CEFZIL
Sponsor Trials
Teva Pharmaceuticals USA 4
Sandoz 4
Ranbaxy Laboratories Limited 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CEFZIL
Sponsor Trials
Industry 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.